|
Correction Alert: Becton Dickinson Updates Use Instructions for BD Alaris Pump Issue
The FDA is aware that Becton Dickinson (BD), a subsidiary of CareFusion 303, Inc., has issued a letter to affected customers recommending users take additional precautions with Alaris Pump Modules that have been dropped or severely jarred. Dropping the Alaris Pump Module may cause damage to internal components that may not be apparent or readily visible, such as damage to the Alaris Pump module bezel assembly, which provides the mechanical foundation for critical pumping components. This damage can cause under-infusion, over-infusion, unregulated flow, or failure of the Alaris Pump module to calibrate.
Over and under infusions can potentially lead to serious adverse health consequences including serious injury and death, depending on the type of drug (and its resulting clinical effect), the patient criticality and magnitude of the flow rate inaccuracy.
As of September 22, 2025, BD has reported two serious injuries, and no deaths associated with this issue.
This recall involves updating instructions for using devices and does not involve removing them from where they are used or sold. The FDA has identified this recall as the most serious type. This device may cause serious injury or death if you continue to use it without following the updated instructions.
Questions?
Customers in the U.S. with adverse reactions, quality problems, or questions about this recall should contact BD Technical Support at 888-812-3229 or via email at DL-US-INF-TechSupport@bd.com. For more contact options, please visit this recall’s webpage.
|
